September 29th, 2020 | 10:51 CEST
BioNTech, Bayer, Valeo Pharma: Share price jump ahead of quarterly results
Table of contents:
Born and raised in Hannover, Lower Saxony follows social and economic developments around the globe. As a passionate entrepreneur and columnist he explains and compares the most diverse business models as well as markets for interested stock traders.
All signs point to success
BioNTech and Valeo Pharma are addressing the issue of the corona pandemic in two different ways. BioNTech is investing a lot of money in research, development, and testing to get a vaccine against Covid-19 ready for the market. The company is also simultaneously building up production capacities to be able to market the highest possible number of vaccine doses as quickly as possible. In the race for a vaccine, different interests come to the fore.
Of national interest
Whoever first brings a vaccine against Covid-19 onto the market will not only have demonstrated competence but will also pave a responsible way out of the restrictions for politicians and industry. Once a vaccine is available to the general public, it is the individual responsibility of citizens to ensure that the protective measure is implemented. The state has thus fulfilled its duty. Those who do not follow the advice and the solution are likely to be more or less left to their own devices, with the consequences.
Much upside, little downside
Valeo Pharma takes a different approach, as it does not carry out its research and development, but focuses on the marketing of drugs that have already been proven to be effective. Valeo Pharma usually works with smaller biotech companies whose focus and expertise is in research and development. With a portfolio of nine different compounds, the company can now generate revenues without being exposed to research risks. From the investors' perspective, this approach means diversified and steady growth.
Investors position themselves
In response to Covid-19, Valeo Pharma has recently launched the commercialisation of Hesperco. According to experts, the active ingredient contained in Hesperco strengthens the immune system and can therefore be used to prevent Covid-19. The product is particularly suitable for the target group that does not want to opt for vaccination and is considering alternative options as a replacement. The share price can gain 13.8% to CAD 1.32 in the run-up to the quarterly results. Operating results were announced today after the close of trading in Canada. The company has been invited to a conference call tomorrow, Wednesday 30 September 2020.
Waiting for the upturn
The Bayer Group, on the other hand, could not attract any attention for a specific active ingredient in the context of the Corona pandemic. However, the company is broadly positioned in the agricultural and pharmaceutical sectors and is expected to benefit in connection with an economic recovery in the coming year. Historically, the company's share is valued at around EUR 55.00, which is low and currently demands a great deal of patience and understanding from investors.
Conflict of interest
Pursuant to §85 of the German Securities Trading Act (WpHG), we point out that Apaton Finance GmbH as well as partners, authors or employees of Apaton Finance GmbH (hereinafter referred to as "Relevant Persons") may in the future hold shares or other financial instruments of the mentioned companies or will bet on rising or falling on rising or falling prices and therefore a conflict of interest may arise in the future. conflict of interest may arise in the future. The Relevant Persons reserve the shares or other financial instruments of the company at any time (hereinafter referred to as the company at any time (hereinafter referred to as a "Transaction"). "Transaction"). Transactions may under certain circumstances influence the respective price of the shares or other financial instruments of the of the Company.
Furthermore, Apaton Finance GmbH reserves the right to enter into future relationships with the company or with third parties in relation to reports on the company. with regard to reports on the company, which are published within the scope of the Apaton Finance GmbH as well as in the social media, on partner sites or in e-mails, on partner sites or in e-mails. The above references to existing conflicts of interest apply apply to all types and forms of publication used by Apaton Finance GmbH uses for publications on companies.
Apaton Finance GmbH offers editors, agencies and companies the opportunity to publish commentaries, interviews, summaries, news and etc. on news.financial. These contents serve information for readers and does not constitute a call to action or recommendations, neither explicitly nor implicitly. implicitly, they are to be understood as an assurance of possible price be understood. The contents do not replace individual professional investment advice and do not constitute an offer to sell the share(s) offer to sell the share(s) or other financial instrument(s) in question, nor is it an nor an invitation to buy or sell such.
The content is expressly not a financial analysis, but rather financial analysis, but rather journalistic or advertising texts. Readers or users who make investment decisions or carry out transactions on the basis decisions or transactions on the basis of the information provided here act completely at their own risk. There is no contractual relationship between between Apaton Finance GmbH and its readers or the users of its offers. users of its offers, as our information only refers to the company and not to the company, but not to the investment decision of the reader or user. or user.